TR200002939T2 - Paroxetine maleate - Google Patents

Paroxetine maleate

Info

Publication number
TR200002939T2
TR200002939T2 TR2000/02939T TR200002939T TR200002939T2 TR 200002939 T2 TR200002939 T2 TR 200002939T2 TR 2000/02939 T TR2000/02939 T TR 2000/02939T TR 200002939 T TR200002939 T TR 200002939T TR 200002939 T2 TR200002939 T2 TR 200002939T2
Authority
TR
Turkey
Prior art keywords
paroxetine maleate
paroxetine
maleate
prevention
preparation
Prior art date
Application number
TR2000/02939T
Other languages
Turkish (tr)
Inventor
Witold Jacewicz Victor
David Jones Alan
Man John
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9807627.6A external-priority patent/GB9807627D0/en
Priority claimed from GBGB9823856.1A external-priority patent/GB9823856D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of TR200002939T2 publication Critical patent/TR200002939T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Abstract

Paroxetine maleat ve bunun hazirlanmasi ve inter alia depresyon tedavisinde ve önlemesindeki kullanimi.Paroxetine maleate and its preparation and use in the treatment and prevention of inter alia depression.

TR2000/02939T 1998-04-09 1999-04-09 Paroxetine maleate TR200002939T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9807627.6A GB9807627D0 (en) 1998-04-09 1998-04-09 Novel compounds
GBGB9823856.1A GB9823856D0 (en) 1998-10-30 1998-10-30 Novel compound

Publications (1)

Publication Number Publication Date
TR200002939T2 true TR200002939T2 (en) 2001-02-21

Family

ID=26313449

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02939T TR200002939T2 (en) 1998-04-09 1999-04-09 Paroxetine maleate

Country Status (18)

Country Link
EP (1) EP1073652A1 (en)
JP (1) JP2002511466A (en)
KR (1) KR20010042552A (en)
CN (1) CN1305474A (en)
AP (1) AP2000001950A0 (en)
AU (1) AU3433499A (en)
BG (1) BG104914A (en)
BR (1) BR9909529A (en)
CA (1) CA2327450A1 (en)
EA (1) EA200001050A1 (en)
HU (1) HUP0103651A3 (en)
ID (1) ID26879A (en)
IL (1) IL138920A0 (en)
NO (1) NO20005037L (en)
PL (1) PL343378A1 (en)
SK (1) SK15032000A3 (en)
TR (1) TR200002939T2 (en)
WO (1) WO1999052901A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231833B1 (en) 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
CH689805A8 (en) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Paroxetine methanesulfonate, process for its preparation and pharmaceutical compositions containing it.
GB9827431D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel compound
GB9827387D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel process
GB9914585D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
NL1017421C2 (en) 2001-02-21 2002-01-15 Synthon Bv Process for the production of paroxetine.
KR100672184B1 (en) 2004-09-21 2007-01-19 주식회사종근당 Paroxetine cholate or cholic acid derivative salts
ITTO20060143A1 (en) * 2006-02-28 2007-09-01 Bridgestone Corp TIRE

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
WO1998056787A1 (en) * 1997-06-10 1998-12-17 Synthon B.V. 4-Phenylpiperidine compounds

Also Published As

Publication number Publication date
ID26879A (en) 2001-02-15
BG104914A (en) 2001-10-31
AP2000001950A0 (en) 2000-12-31
PL343378A1 (en) 2001-08-13
AU3433499A (en) 1999-11-01
CN1305474A (en) 2001-07-25
SK15032000A3 (en) 2001-04-09
CA2327450A1 (en) 1999-10-21
JP2002511466A (en) 2002-04-16
KR20010042552A (en) 2001-05-25
NO20005037L (en) 2000-12-05
EA200001050A1 (en) 2001-04-23
WO1999052901A1 (en) 1999-10-21
BR9909529A (en) 2000-12-12
IL138920A0 (en) 2001-11-25
NO20005037D0 (en) 2000-10-06
EP1073652A1 (en) 2001-02-07
HUP0103651A3 (en) 2002-12-28
HUP0103651A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
DE60010098D1 (en) 28-EPIRAPALOGE
TR200103216T2 (en) Pyrimidinone compositions
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
BR9916857A (en) 4 heteroaryl diarylamines
DK0760848T3 (en) Lactobacillus strains of human origin, their compositions and their use
TR200100054T2 (en) Paroxetine methanesulfonate
MXPA02004770A (en) Therapeutic compositions and methods of use thereof.
PT1212317E (en) INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF OSTEOPOROSIS BETWEEN OTHER APPLICATIONS
MXPA02003174A (en) Novel combination of loteprednol and antihistamines.
DE60001735D1 (en) 1-AMINOTRIAZOLO 4,3-A CHINAZOLIN-5-ONE AND / OR -THIONE INHIBITORS OF PHOSPHODIESTERASES IV
SE9904377D0 (en) Pharmaceutical combinations
YU13301A (en) Muscarinic agonists and antagonists
AU2002366201A1 (en) Use of defined copolymers as adjuvants and agents in the agrotechnical domain
MXPA01010403A (en) Osteopontin-derived chemotactic and inhibitory agents and uses therefor.
PT946175E (en) USE OF A COMBINATION OF H +, K + -ATPASE AND GLUCOCORTICIOD INHIBITORS IN THE TREATMENT OF NASA POLLS
TR200002939T2 (en) Paroxetine maleate
EP1441761A4 (en) Methods of preventing and treating flavivirus infection in animals
BR9506389B1 (en) silicon, and dietary, cosmetic and therapeutic composition.
ES2175356T3 (en) USE OF (+) - ALPHA- (2,3-DIMETOXIFENIL) -1- [2- (4 FLUOROFENIL) ET IL [-4- PIPERIDINMETANOL IN THE TREATMENT OF DEPRESSIVE DISORDERS AND BIPOLAR DISORDERS.
DE60118910D1 (en) PHOSPHATE CONVERSION PROCESSING AND COMPOSITION
DE69911104D1 (en) Static binding of dynamically sent calls in the presence of dynamic linkage and charging
DE29907084U1 (en) Table and chair combination
EA200000909A1 (en) FORM VI 5,6-DICHLOR-2- (ISOPROPYLAMINO) -1- (b-L-RIBOFURANOSIL) -1H-BENZIMIDAZOLE
IT1309453B1 (en) BIOARTIFICIAL SUBSTRATE FOR THE REALIZATION OF FABRICS AND ORGANIANIMALS, IN PARTICULAR HUMAN.
AU143942S (en) Controller device